@article{fdi:010088923,
  title = {{COVAX} - {T}ime to reconsider the strategy and its target},
  author = {{B}ell, {D}. and {B}rown, {G}. {W}. and {O}yibo, {W}. {A}. and {O}uedraogo, {S}. and {T}acheva, {B}. and {B}arbaud, {E}. and {K}alk, {A}. and {R}idde, {V}al{\'e}ry and {P}aul, {E}.},
  editor = {},
  language = {{ENG}},
  abstract = {{COVAX}, the international initiative supporting {COVID}-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion {US} dollars already committed. {W}hile some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. {F}irst, mass {COVID}-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. {S}econd, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. {W}e conclude that the {COVAX} initiative warrants urgent review.},
  keywords = {},
  booktitle = {},
  journal = {{H}ealth {P}olicy {O}pen},
  volume = {4},
  numero = {},
  pages = {100096 [6 ]},
  year = {2023},
  DOI = {10.1016/j.hpopen.2023.100096},
  URL = {https://www.documentation.ird.fr/hor/fdi:010088923},
}